Advertisement

Topics

Companies Related to "Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery" [Most Relevant Company Matches] RSS

21:26 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery" found in our extensive corporate database of over 50,000 company records.

Showing "Effect Amide Myocardial Function Following Coronary Artery Bypass" Companies 1–25 of 764

Extremely Relevant

Ischemix

Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary interve...


VasoPrep Surgical, LLC

VasoPrep Surgical, LLC is a privately-held medical device company headquartered in Morristown, New Jersey, with manufacturing and distribution partners in the United States and Europe. The Company is focused on preservation of the structure and function of autotransplanted vessels used in peripheral vascular bypass/reconstruction and coronary artery bypass...

Cardica

Cardica designs and manufactures proprietary automated anastomotic systems used by surgeons to perform coronary artery bypass graft (CABG) surgery. In CABG procedures, veins or arteries are used to construct alternative conduits to restore blood flow beyond narrowed or occluded portions of coronary arteries, "bypassing" the narrowed or occluded portion of the artery that is impairing blood flow to...


PLC Systems

PLC is a global leader in the development of products for performing a revolutionary new surgical procedure known as transmyocardial revascularization (TMR). TMR offers a completely new medical treatment option for patients who suffer from severe coronary artery disease. Coronary artery disease is the leading cause of death in the United States. Working with leading researchers and premier heart...

PQ Bypass

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions.

PQ Bypass, Inc.

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions.

EPIX Medical Incorporated

Based on its core, proprietary technology, EPIX is advancing its pipeline of products such as MS-325, the Company's lead MRI contrast agent currently in Phase III trials. MS-325 is also in development to help diagnose coronary artery disease, breast cancer, female sexual arousal dysfunction, atherosclerosis and myocardial perfusion. In addition to MS-325, EPIX's pipeline includes a new class of MR...

PlaqueTec Ltd.

PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory risk. It has been proven to detect inflammatory molecules across the site of coronary artery disease (CAD), and can discriminate between patients with greater and lesser levels of co...

Kips Bay Medical, Inc.

Kips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a development stage medical device company focused on developing, manufacturing and commercializing its eSVS MESH for use in coronary artery bypass grafting surgery. Additional information about Kips Bay Medical, Inc. can be found at www.kipsbaymedical.com.

Relevant

EPIXMedical Incorporated

EPIX's goal is to transform the management and diagnosis of vascular disease through the development of targeted MRI contrast agents. Based on its core, proprietary technology, EPIX is advancing its pipeline of products such as MS-325, the Company's lead MRI contrast agent currently in Phase III trials. MS-325 is also in development to help diagnose coronary artery disease, breast cancer, female s...

The Hope Heart Institute

The Hope Heart Institute was founded in 1959 by Lester R. Sauvage, MD, a world-renowned cardiovascular surgeon and research scientists. Dr. Sauvage and The Hope earned international recognition in 1962 through pioneering coronary artery bypass graft (CABG) surgery. Today, The Hope's research remains at the forefront of the cardiovascular field—and our health education publications reach nearly 5...

CardioTech International

CardioTech is developing a family of small bore vascular graft devices using specialized Chronoflex ® polyurethane materials that it believes will provide significantly improved performance in the treatment of cardiovascular disorders. CardioTech's research and development efforts are concentrated on the development of vascular access grafts, peripheral grafts, and coronary artery bypass grafts....

Kips Bay Medical Inc.

Kips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, or eSVS MESH for use in coronary artery bypass grafting surgery. The eSVS MESH is a nitinol mesh sleeve that, when placed over a saphenous vein graft du...

EndoCross, Ltd.

Privately held EndoCross Ltd., headquartered in Yokneam Israel, and with operations in Amherst, New Hampshire (USA), has developed a proprietary system for the crossing of Chronic Total Occlusion (CTO). Through a combination of a unique balloon catheter design and the incorporation of a novel automated inflation system, the company’s ENABLER Catheter ...

Rcadia Medical Imaging Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The COR Analyzer...

Cardica, Inc.

Cardica designs and manufactures proprietary stapling devices for cardiac and endoscopic surgical procedures. Cardica's stapling technology minimizes operating time and enables minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port(R) Distal Anastomosis Systems and PAS-Port(R) Proximal Anastomosis System, for coronary artery ...

Rcadia Medical Imaging

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

Rcadia Medical Imaging, Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

t2cure GmbH

t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases like myocardial infarction or peripheral artery occlusive disease.

Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD), specifically bifurcation disease. Cappella’s initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating...

Cappella Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary ...

Cappella Medical Devices Ltd

Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the ...

HeartFlow, Inc.

HeartFlow, Inc., based in Redwood City, Calif., is pioneering technology designed to help physicians noninvasively diagnose coronary artery disease, improve patient outcomes and reduce health care costs. For more information visit www.heartflow.com.

CathWorks

CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize PCI therapy decisions and elevate coronary angiography from visual assessment to an objective FFR-based decision-making tool for physicians. FFR-guided PCI decision-making is proven to provide significant clinical benefits for patients with...

Cappella Medical Devices Limited

Cappella, Inc. develops novel solutions for the treatment of complex coronary artery disease (CAD) - specifically bifurcation disease. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, solution that focuses on treating the sidebranch of diseased coronary arteries first, rather tha...


More From BioPortfolio on "Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks